- Home
- ARR vs MLYS Comparison
ARR vs MLYS Comparison
Compare ARR & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ARR | MLYS |
|---|---|---|
| Founded | 2008 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.2B |
| IPO Year | N/A | 2023 |
Fundamental Metrics
Financial Performance| Metric | ARR | MLYS |
|---|---|---|
| Price | $17.10 | $23.62 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | $18.50 | ★ $48.67 |
| AVG Volume (30 Days) | ★ 2.7M | 1.8M |
| Earning Date | 04-22-2026 | 05-06-2026 |
| Dividend Yield | ★ 16.69% | N/A |
| EPS Growth | N/A | ★ 37.43 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $27.18 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.98 | $12.59 |
| 52 Week High | $19.31 | $47.65 |
Technical Indicators
Market Signals| Indicator | ARR | MLYS |
|---|---|---|
| Relative Strength Index (RSI) | 51.10 | 37.91 |
| Support Level | $17.04 | $22.42 |
| Resistance Level | $17.24 | $31.29 |
| Average True Range (ATR) | 0.26 | 1.52 |
| MACD | 0.02 | -0.56 |
| Stochastic Oscillator | 74.07 | 16.41 |
Price Performance
Historical ComparisonAbout ARR ARMOUR Residential REIT Inc.
ARMOUR Residential REIT Inc operate in the U.S. and invest in fixed rate residential, adjustable rate and hybrid adjustable rate residential MBS issued or guaranteed by U.S. GSEs or guaranteed by Ginnie Mae. It also invest in U.S. Treasury Securities and money market instruments.
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.